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I. INTRODUCTION
In Europe fifty years ago, "doctors" and "researchers" con-
ducted experiments on human beings under horrendous circum-
stances. Prisoners in Nazi concentration camps were exposed to
a multitude of diseases including malaria, jaundice, and typhus
to see how the diseases grew.1 The prisoners were then sub-
jected to numerous untested antibiotics, not for their own bene-
fit, but for the purpose of the research itself.2 The Nazis also
conducted altitude and freezing experiments in which individu-
als were subjected to extreme altitudes and extreme cold with-
out any protection from the elements. 3 "Doctors" then charted
the reactions of the human bodies to these conditions.4 Those
subjects who did not die from the disease research or the alti-
tude and freezing experiments were either subjected to more
"medical" tests or executed. 5 The research and the experiments
conducted by the Nazis were, of course, not designed to benefit
the actual human subjects involved. On the contrary, no regard
at all was given to the welfare of these subjects; rather, they
were the victims of torture. 6
Following Allied victory in Germany, many of those respon-
sible for these atrocities were tried at Nuremberg. 7 The Nurem-
1 See Matthew Lippman, The Nazi Doctors Trial and the International Prohi-
bition on Medical Involvement in Torture, 15 Loy. L.A. INT'L. & COMP. L.J. 395,
410-12.
2 See id.
3 See id.
4 See id.
5 For more detail on Nazi experiments see id.; see also WILLIAM L. SHIRER,
THE RISE AND FALL OF THE THIRD REICH: A HISTORY OF NAzi GERMANY 985 (1960);
see also THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN
EXPERIMENTATION, (George J. Annas & Michael A. Grodin eds., 1992). [hereinafter
NAZi DOCTORS].
6 See Lippman, supra note 1, at 412.
7 See Trials of War Criminals before the Nuremberg Military Tribunals
under Control Council Law No. 10: Nuremberg, October 1946-1949 (U.S. Govern-
ment Printing Office, 1949) reprinted as The Nuremberg Code, in SOURCEBOOK IN
BIOETHICS: A DOCUMENTARY HISTORY 11 (Albert R. Jonsen, et al., ed. 1998); also
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berg trials resulted in the first enunciation of ethical principles
for medical research involving human beings-the Nuremberg
Code.8 The trials also ignited the first international debate
about the creation of standards that would allow for effective
research while ensuring that people are not treated as guinea
pigs.
Unfortunately, the Nazis are not the only group responsible
for committing wrongdoing in the name of medical or scientific
research. Thirty years ago, in the United States, the Tuskegee
medical experiments came to light.9 These experiments, which
went on for decades, involved the denial of effective medical
treatment to certain black men suffering from syphilis.' 0 Even
when it became apparent that penicillin was capable of com-
pletely curing the disease, the drug was withheld to allow re-
searchers to continue studying the course of the disease.', The
apparent justification for this course of action was the fact that
the subjects did receive some degree of medical care through the
study. It was argued that but for the subjects' participation in
the study, they would have received no treatment for the dis-
ease at all.12
The men in this study were not only denied effective medi-
cal treatment, the researchers actively deceived them. They
were told neither that they had syphilis nor that there was a
cure for the disease. 13 Researchers Fairchild and Bayer suc-
cinctly describe the abuses of this experiment:
The study involved, first, deceptions regarding the very existence
and nature of the inquiry into which individuals were lured. As
such, it deprived those seeking care of the right to choose whether
or not to serve as research subjects. Second, it entailed an ex-
ploitation of social vulnerability ... Finally, Tuskegee research-
reprinted in NAzI DOCTORS, supra note 5, at 137 [hereinafter The Nuremberg
Code]. The Nuremberg Code was part of the judgment rendered against the Nazi
doctors. See id.
8 See id.
9 See Marcia Angell, The Ethics of Clinical Research in the Third World, re-
printed in TUSKEGEE'S TRUTHS 578, 578 (Susan M. Reverby, ed. 2000) [hereinafter
Clinical Research].
10 See generally JAMES H. JONES, BAD BLOOD (1993).
11 See id. .
12 See Clinical Research, supra note 9, at 579.
13 See Amy L. Fairchild & Ronald Bayer, The Uses and Abuses of Tuskegee,
reprinted in TUSKEGEE'S TRUTHS, supra note 9, at 590.
20011
3
PACE INT'L L. REV.
ers made a willful effort to deprive subjects of access to
appropriate and available medical care...14
When the Tuskegee experiment was made public, it
spawned the creation of enforceable Food and Drug Administra-
tion Rules (FDA Rules) for the conduct of medical experiments
in the United States. 15 Among other things, the FDA Rules
rendered illegal medical tests conducted with placebos 16 in
cases in which there was a known therapy for the disease. 17
The rules further required that researchers secure informed
consent from their subjects prior to the performance of any
medical experiments.' 8
While the FDA Rules represent progress in terms of re-
search ethics, serious problems remain to be addressed. Some
of these problems stem from diseases like AIDS that have chal-
lenged traditional research. The increase in infectious diseases
such as AIDS, the lack of family planning assistance, and the
lower cost of conducting experiments in developing nations
make the developing world a prime spot for drug experimenta-
tion. 19 This research is performed, for the most part, for the
benefit of humankind, yet drug research in the developing
world presents new, unsolved, ethical dilemmas.
While strict rules often apply to research conducted within
the United States and within many European countries, when
researchers from the United States and Europe perform re-
search in developing nations, they are largely free from such
research limitations. The research performed in developing na-
14 Id. at 590.
15 See Federal Food, Drug, and Cosmetic Act, 21 C.F.R. §50, 45 C.F.R.
§46.116; 21 U.S.C. §301.
16 Patients given a placebo are given a non-drug such as vitamin C or a sugar
pill. See MERRIAM-WEBSTER'S MEDICAL DESK DICTIONARY (1996). Placebo groups
are then compared to groups of people receiving treatment to study the effective-
ness of a particular treatment. See id.
17 See Bill Sloat & Keith Epstein, Living Proof Ugandans in American-Run
Study expected treatment, but some pills were dummies, THE PLAIN DEALER, Nov. 9,
1998, at 1A [hereinafter Ugandan Study].
18 See 21 C.F.R. §50.20, 45 C.F.R. §46.116.
19 See New $150m Initiative to Combat AIDS and Contribute to internation-
al prevention efforts, M2 PRESSWIRE, January 11, 2000, available at 2000 WL
4795162 [hereinafter AIDS initiative].
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tions is, therefore, often suspect.20 The potential for abuse is
significantly increased when vulnerable groups are involved in
this research. 21 Women and children, for example, are often re-
garded in developing nations as wards of the state. 22 Further-
more, principles of informed consent often give way to state
fears of disease and to the desire for expedient research.
23
There is increasing concern that U.S. and European drug com-
panies are moving testing to less developed nations where
"costs are low, patients are plentiful, and government oversight
lax."24 This article argues that developed nations need to do
more to protect the rights of people in less developed nations
from unnecessary and unscrupulous medical experiments, par-
ticularly drug experiments.
Part II of this paper will explore the historical development
of the rules for ethical research, specifically the first documents
regarding the use of humans in research. It will then describe
both the FDA Rules regarding drug testing and the provisions
of the European Convention on Biomedicine. Finally, it will ad-
dress current international rules, regulations, and ethical
guidelines regarding medical testing to determine whether in-
ternational law is capable of filling in where domestic laws do
not. Part III will explore the current problem of testing in those
countries where medical standards may not be compatible with
those standards adopted by developed countries. It will explain
the current fear regarding infectious diseases and overpopula-
tion, and it will discuss how these fears can lead governments to
put their own citizens at risk. It will further note how devel-
oped nations' drug companies may take advantage of the poor,
the sick, and the dying, particularly women and children. Fi-
nally, it will explore the problem of informed consent and other
standard procedures that may, in fact, be inadequate to protect
20 See Charles W. Henderson, CEL-SCI Announces Data from Phase II Study,
AIDS WEEKLY, December 13, 1999, available at 1999 WL 10041741.
21 See M. Dickens, Research Ethics and HIV/AIDS, 16 MED. & L. J. 196
(1997).
22 See Kevin M. King, A Proposal for Effective International Regulation of Bi-
omedical Research Involving Human Subjects, 34 STANF. J. INT'L. L. 163, 192
(1998) [hereinafter Effective International Regulation].
23 See id. at 192.
24 Mary Pat Flaherty & Joe Stephens, Pa. Firm Asks FDA to Back Experiment
Forbidden in U.S., WASH. POST A03, February 23, 2000, available at 2001 WL
2546189.
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people in these countries. Finally, Part IV will explore possible
solutions to the problem of medical experimentation in develop-
ing nations as well as the limits of those solutions.
II. THE RULES
A. Nuremberg and Helsinki: The First Ethical Documents
At the end of World War II, the world was horrified to learn
of the medical experiments conducted by Nazi doctors in con-
centration camps.25 These experiments ultimately led to the
creation of the Nuremberg Code (Nuremberg Code or Code), the
first articulation of standards for medical research involving
human subjects. 26 The Code sets out ten requirements for
human research including voluntary consent, the avoidance of
unnecessary pain and suffering for the subjects, and the right of
the subject to withdraw at any time.27 The Code clarifies "con-
sent" as follows: 1) a person must have legal capacity to consent;
2) a person must be free to exercise choice without fraud, du-
ress, deceit or constraint; 3) and a person must have sufficient
comprehension of the nature of the experiment and the treat-
ment to enable him to understand the decision he is making.28
In addition to consent, the Code requires that an experiment
should only be conducted where a societal good will result.29
The Code, however, does not explicitly address the use of place-
bos or vulnerable populations in research.
Unfortunately, the international community never offi-
cially adopted the Nuremberg Code. 30 In addition, its creation
25 See generally NAzI DOCTORS, supra note 5.
26 See The Nuremberg Code, supra note 7.
27 See id. Other provisions of the Code include the requirement that tests not
be random or unnecessary and that they be based on adequate animal and other
research. Research that doctors believe will result in death or disabling injury is
prohibited. The Code also requires that there be proper facilities for the research
subject and that only a qualified professional conduct research. The risk of the
experiment must be in proportion to the danger of the disease to society. Finally,
the researcher is required to terminate the research if at any time in his profes-
sional judgment disabling injury or death might result. Id.
28 See id.
29 See id.
30 See George J. Annas & Michael A. Grodin, Medical Ethics and Human
Rights: Legacies of Nuremberg, 3 HOFSTRA L. & POL'Y SYMP. 111, 113-14 (1999).
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during the Nuremberg Trials 31 left the impression that it was
formed solely in response to the horrible experiments of Nazi
Germany rather than to provide a code for medical experiments
today.32 The Code responded to experiments that clearly were
performed against the will of the human subjects, all of whom
were prisoners of the Nazi state. 33 Furthermore, the experi-
ments were clearly not intended for the benefit of the subject or
the subject's community. 34 Thus, the Code was a response to
purely non-therapeutic research.35 As a result, those in the bi-
omedical field (both law and science) differ on the effectiveness
of the Code in preventing abuses in international medicine.
36
In addition, many have questioned the applicability of its more
stringent provisions when the research is clearly for the benefit
of the patient.37
In response to the Code, the World Physician's Organiza-
tion38 formed and wrote the Helsinki Declaration.39 The Hel-
sinki Declaration separates therapeutic and scientific
research. 40 The former occurs for the benefit of the individual
patient, while the latter is research performed purely to achieve
31 The Nuremberg Trials were instituted by the allies following World War II
in order to try various Nazi criminals. The Doctor's Trials were a part of that
process. See The Nuremberg Code, supra note 7.
32 See generally Annas & Grodin, supra note 29.
33 See Sharon Perley, et al., The Nuremberg Code: An International Overview,
in NAzI DOCTORS, supra note 5, at 150.
34 See id.
35 See id.; see also Leonard H. Glantz, The Influence of the Nuremberg Code on
U.S. Statutes & Regulations, in NAZI DOCTORS, supra note 5, at 183-85.
36 See Perley, supra note 33, at 150; see also generally Annas & Grodin, supra
note 30.
37 See, e.g., THE ETHICS OF RESEARCH INVOLVING HUMAN SUBJECTS FACING
THE 21sT CENTURY, 8 (Harold Y. Vanderpool, ed. 1999) [hereinafter FACING THE 21sT
CENTURY].
38 The World Physicians Organization was a body of medical professionals
governed by medical professionals. It was formed in large part to create guidelines
that were not as severe as the Nuremberg Code. For a more complete discussion
on the formation of this organization, the Helsinki Guidelines, and subsequent de-
velopments see George J. Annas, The Changing Landscape of Human Experimen-
tation Nuremberg, Helsinki, and Beyond, 2 HEALTH MATRIX 119 (1992) [hereinafter
Changing Landscape]; see also Declaration of Helsinki: Recommendations Guiding
Medical Doctors in Biomedical Research involving Human Subjects, reprinted in
SOURCEBOOK IN BIOETHICS, supra note 7, at 13 [hereinafter Helsinki Declaration].
39 See Helsinki Declaration, supra note 38.
40 See id.
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scientific knowledge. 41 The treatment of the patient is different
under the two standards. The consent of the patient is not re-
quired for therapeutic treatment if the physician researcher,
acting in the best interest of the patient, believes that informed
consent would be too difficult and unnecessary. 42 On the other
hand, experimentation conducted with little or no expectation of
direct benefit to the patient requires full consent.43 Drug re-
search is somewhat ambiguous in this respect. For example, ex-
perimental drugs may be included in therapeutic treatment,
but they may be given with little expectation of benefiting the
patient. The difference between the two types of research is,
therefore, often blurred.
In addition to the guidelines for consent, the Helsinki Dec-
laration also requires that patients undergoing experimental
treatment, including members of a control group, should always
be provided with the "best proven diagnostic and therapeutic
methods."44 The overriding principle of the Declaration is that
"concern for the interests of the subject must always prevail
over the interest of science and society."45
The Nuremberg Code and the Helsinki Declaration have
served as the basis for the creation of national and interna-
tional rules governing biomedical research on humans.46 Yet,
despite their influence, there is great debate as to whether ei-
ther has been adopted as binding customary international
law. 47 In light of the absence of a consensus on international
law in this area, national laws regarding experimentation are
significant.
41 See id.
42 See id.
43 See Helsinki Declaration, supra note 38, at 13.
4 See id. at 14.
45 See id. at 14.
46 See George J. Annas & Michael Grodin, Conclusions, in NAZI DOCTORS,
supra note 5, at 311-13.
47 See Changing Landscape, supra note 38, at 3 (for a further discussion on
whether the Nuremberg Code or Helsinki Declaration are binding customary in-
ternational law or merely ethical guidelines). Note, however, that United States
Courts have cited the Nuremberg Code as binding authority. See e.g., United
States v. Jaffe, 663 F.2d 1226 (3d Cir. 1981); United States v. Stanley, 483 U.S.
669 (1987).
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B. United States Food and Drug Administration Rules
The FDA Rules state that research is only permissible with
"the legally effective informed consent of the subject or the sub-
ject's legally authorized representative. '48 Informed consent is
further defined by several elements including the provision of a
description of the study and its purposes, disclosure of any fore-
seeable adverse or beneficial effects, and notification of any al-
ternative treatments available. 49 The subject must also be
informed of the freedom to withdraw from the project at any
time as well as the process for doing So. 5 0 The non-military ex-
ceptions to informed consent are very narrow. 51 To bypass in-
formed consent, a physician must certify the following: 1) that
the subject confronts a life threatening situation; 2) that in-
formed consent cannot be obtained from the subject; 3) that
time is not sufficient to gain consent from the legal representa-
tive; and 4) that there are no other available methods of treat-
ment.52 It is important to note that if the subject or the
subject's legal guardian is capable of consenting, then consent
must be obtained under the guidelines. 53 The rules also offer
great detail regarding the process of setting up an independent
review board to approve and monitor the experiment. 54 Where
an independent review board is established, there is greater lat-
itude in obtaining consent.5 5 If such a board determines that
obtaining consent is not practicable and that there is no more
than a minimal risk to the patients involved, consent may be
entirely waived.56
In cases involving pregnant women, the FDA Rules addi-
tionally require that the research be intended to help the
mother and that the fetus will not be placed at great risk.
57
Children and prisoners are also given particular protections be-
48 See 21 C.F.R. §50.20
49 See 21 C.F.R. §50.25
50 See id.
51 See 21 C.F.R. §50.23, §50.24.
52 See 21 C.F.R. §50.23.
53 See id.
54 See 45 C.F.R. §46.107-115.
5 See 45 C.F.R. §46.116 (c)(d).
56 See 45 C.F.R. §46.205.
57 See 45 C.F.R. §46.207.
20011
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cause of their increased vulnerability.58 Importantly, however,
unless the research in question is conducted or funded by the
United States' government, the FDA Rules apply only within
the borders of the United States. 59
C. European Convention on Biomedicine60
The European Convention on Biomedicine (European Con-
vention) recognizes "the primacy of the human being" in medi-
cal research.61 Several conditions must be met prior to the
beginning of research. 62 While the consent of the subject is re-
quired prior to experimental treatment,63 the subject need only
be given "appropriate information as to the purpose and nature
of the intervention as well as on its consequences and risks."64
If a child subject is involved, a legal guardian must give con-
sent, but the child's opinion will also be considered. 65 Even af-
ter granting consent, the subject may at any time withdraw
such consent.66 Finally, just as is also true under the FDA
Rules, the European Convention enables a physician to avoid
informed consent if obtaining such consent is not practicable
and if the action taken is for the direct benefit of the subject.67
In order for research to be conducted on human subjects
under the European Convention, the following conditions must
be met: 1) no comparable alternative research is capable of be-
ing undertaken; 2) the risks to the person are not disproportion-
ate to the benefits; 3) an independent review board has
approved the research; 4) the subjects have been informed of
58 See 45 C.F.R. §46.306 (prisoners) and 45 C.F.R. §46.405 (children).
59 See 45 C.F.R. §46.101(a)(1)(2).
60 It is important to remember that each European country has its own ethical
code. The European Convention on Biomedicine is used here because of the
limitations of this article and also because of its place as a representative
document. For a brief analysis of various national European laws see ARTHUR
ROGERS AND DENIS DURAND DE BOUSINGEN, BIOETHICS IN EUROPE (1995).
61 Convention on Human Rights and Biomedicine, Apr. 4, 1997, E.U., Europ.
T.S. No. 164, (entered into force Jan. 12, 1999) reprinted in 36 I.L.M. 817, 821 (July
1997) [hereinafter European Convention on Biomedicine].
62 See id. at art. 5, art. 16. These conditions are similar to those required
under the Helsinki Declaration. See generally Helsinki Declaration, supra note 38.
63 See European Convention on Biomedicine, supra note 61, art. 5.
64 See id.
65 See id. art. 6(2).
66 See id. art. 16(v).
67 See id. art. 6(1).
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their rights; and 5) adequate informed consent has been
given.68 It is important to note that the European Convention
was intended to embody broad guidelines that would begin to
unify practices in the European Union.69 The national laws of
each country provide more detailed regulation of research.
70
Given that the European Convention must be acceptable to sev-
eral European nations, it is understandably less detailed than
the FDA Rules. 71
D. International and Multinational Documents
1. World Ethical Agreements Beyond Nuremberg and
Helsinki
Following the first Helsinki Declaration and its revision,
the Council for International Organizations of Medical Sciences
(CIOMS) and the World Health Organization (WHO) created
the Proposed International Guidelines for Biomedical Research
Involving Human Subjects (Bioethics Guidelines).72  The
Bioethics Guidelines, revised in 1992, "contained restrictions on
the use of pregnant and nursing women, prisoners, children,
and persons with mental or behavioral disorders. 7 3 The
Bioethics Guidelines was also the first international document
to specifically address the problems of international medical re-
search in developing nations.74 The Bioethics Guidelines ad-
68 See id. art. 16.
69 See Council of Europe Directorate of Legal Affairs, Explanatory Report to
the Convention for the Protection of Human Rights and Dignity of the Human Be-
ing with Regard to the Application of Biology and Medicine: Convention on Human
Rights and Biomedicine 4, reprinted in, 36 I.L.M. 826, 827 (January 1997).
70 See id. at $7; see also European Convention on Biomedicine, supra note 61,
art. 4.
71 Compare European Convention on Biomedicine, supra note 61, at art. 5
with 21 C.F.R. §50.20-25 and 45 C.F.R. §46.116 (both detailing guidelines for in-
formed consent).
72 See International Ethical Guidelines for Biomedical Research Involving
Human Subjects (1993) [hereinafter International Ethical Guidelines], reprinted
in BEYOND REGULATIONS: ETHICS IN HUMAN SUBJECTS RESEARCH (Nancy M.P.
King, et al., eds. 1999) [hereinafter BEYOND REGULATIONS].
73 Effective International Regulation, supra note 22, at 183.
74 See, e.g., International Ethical Guidelines, supra note 72, at guidelines 8,
10, 15 (for provisions specifically referencing rights and responsibilities where re-
search involves developing nations).
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dress the problems of research in developing nations75 by
requiring that before research may begin, the researcher must
certify the following: 1) that the research could not be carried
out reasonably well in more developed communities; 2) that the
research is responsive to the health needs of the community; 3)
that every effort will be made to obtain informed consent; and 4)
that the research has been approved by a review board familiar
with the community in question.76 In those cases in which re-
search is sponsored by the researchers of one nation but is con-
ducted in another nation (externally sponsored research), the
Bioethics Guidelines specify that the research must pass ethical
review in the researchers' home nation as well as in the nation
hosting the research.77 In addition, the Bioethics Guidelines
contain an equitable principle that the community that bears
the burden of the experiment should also be the community to
receive benefits from the research. 78
Because of growing research in the area of diseases, CI-
OMS also created the International Guidelines for Ethical Re-
view of Epidemiological Studies (Epidemiological Guidelines).79
The preamble requires protection of vulnerable populations.80
In addition to reinforcing the requirements of the Bioethics
Guidelines, the Epidemiological Guidelines stress the need to
ensure that participants in developing communities do not con-
sent to research merely to receive much needed health care.8 '
They also explain and emphasize the importance of training lo-
cal health professionals to continue care for the participants af-
ter the foreign researchers have departed. 2  The
Epidemiological Guidelines also note the need for cultural sen-
75 It is important to note that a "developing community" refers to both an un-
derdeveloped nation and an underdeveloped part of a developed nation. See id. at
art. 8; see also Community-based HIV Research, in BEYOND REGULATIONS supra
note 72, at 82-107.
76 See International Ethical Guidelines, supra note 72, at guideline 8.
77 See id. at guideline 15. As used in this article, home country refers to the
place the researchers are based out of, usually a developed nation. Host country
refers to the place where research occurs, usually a developing nation.
78 See id. at guideline 10.
79 See CIOMS, International Guidelines for Ethical Review of Epidemiological
Studies (Geneva 1991) [hereinafter Epidemiological Guidelines], reprinted in BE-
YoND REGULATIONS, supra note 72, at 239.
80 See id. at preamble.
81 See id. at guideline 11.
82 See id at guideline 17.
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sitivity in research, and they continue to require that research-
ers not conduct research that would be considered unethical in
their home nations.83
Both the Bioethics Guidelines and the Epidemiological
Guidelines clearly indicate that they are persuasive only; they
do not embody law or regulation.8 4 Thus, although the persua-
sive ethical intent of these documents is evident, nations are
not bound to require their researchers to act in accordance with
their principles. Nor is there any enforcement mechanism for
violations of either set of guidelines.
2. Human Rights Conventions
International human rights law and ethics are closely re-
lated.8 5 A fundamental concept of both ethics and current
human rights law is human dignity. 6 International treaties
and declarations repeatedly prohibit conduct that destroys
human dignity. International law prohibits torture, slavery,
and genocide, and it promotes the right to life and the right to
humane treatment.8 7 Thus, medical experiments that violate
the principles of human dignity are likely to be condemned.
The United Nations (U.N.), as a body, has issued no specific
declaration regarding human testing, nor has there been any
international treaty dealing specifically with this issue.8 8
There are, however, a multitude of organizations within the
U.N. that have issued statements regarding human experimen-
tation, and several U.N. treaties have offered broad statements
regarding medical testing.8 9 The strongest of these statements
is that found in the International Covenant on Civil and Politi-
cal Rights (ICCPR).90 The ICCPR states, "no one shall be sub-
jected without his free consent to medical or scientific
83 See id. at guideline 25.
84 See NAZI DOCTORS, supra note 5, at 161.
85 See MALCOM M. SHAW, INTERNATIONAL LAW 197 ( 4 th ed. 1997).
86 See id. at 198.
87 See generally id. at 203-04.
88 See Sonia Le Bris, et al., International Bioethics, Human Genetics, and
Normativity, 33 Hous. L. REV. 1363, 1365 (1997).
89 See id.
90 International Covenant on Civil and Political Rights, Dec. 16, 1966, 999
U.N.T.S. 171 (entered into force Mar. 23, 1976), G.A. Res. 2200 A, U.N. GAOR, 21st
Sess., Supp. No. 16, at 49, U.N. Doc. A/0316 (1966), available at http:fl
www.umn.edu/humanrt/instree/b3ccpr.htm. [hereinafter ICCPR].
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experimentation." 91 The principle of informed consent is, there-
fore, clearly present in international law.
Another concept found throughout international human
rights law is that of bodily integrity. This concept could serve
as a basis for condemning improper human experimentation. 92
For example, the Universal Declaration of Human Rights states
"[elveryone has the right to life, liberty and the security of per-
son."93 In fact, the concepts of "bodily integrity" and "security of
person" are standard provisions of human rights conventions
throughout the world. 94
Although the U.N. as a whole has not yet issued a declara-
tion on the subject, various human rights branches of the U.N.
have issued declarations on the issue of human experimenta-
tion. The High Commission on Human Rights issued the Reso-
lution on Human Rights and Bioethics,95 and The World
Conference on Human Rights addressed the issue of human ex-
perimentation in the Vienna Programme of Action (Vienna Pro-
gramme). 96 The Vienna Programme echoes the Covenant on
Economic, Social and Cultural Rights 97 in stating that everyone
has the right "to enjoy the benefits of scientific progress and its
applications."9 The Vienna Programme goes on to recognize
the problems inherent in the current advances of biomedicine
91 Id. art. 7.
92 For a discussion of the possible use of "bodily integrity" as a means of in-
volving international law in bioethics see Effective International Regulation, supra
note 22, at 173-8.
93 Universal Declaration of Human Rights (UDHR), art. 3.
94 See Convention for the Protection of Human Rights and Fundamental Free-
doms, art. 5(1) Apr. 11, 1950, Europ., 213 U.N.T.S. 222, (entered into force Sept. 3,
1953); American Convention on Human Rights, art. 7(1) Nov. 22, 1969, 1144
U.N.T.S. 123 (entered into force July 18, 1978), reprinted in 9 I.L.M. 673 (1969);
African Charter on Human and Peoples' Rights (Banjul Charter), arts. 4, 6 June
27, 1981, reprinted in 21 I.L.M. 59 (1981) arts. 4, 6.
95 Resolution on Human Rights and Bioethics, E.S.C. Res. 1993/91, U.N. ES-
COR, Hum. Rts. Comm., 4 9 t' Sess., 6 7 th mtg., Supp. No. 3, at 267, U.N. Doc. E/
CN.4/ 1993/122 (1992).
96 Vienna Declaration and Programme of Action, U.N. GAOR, 4 8 th Sess., pt. I,
11, U.N. Doc. A/Conf. 157/24 (1993), reprinted in 32 I.L.M. 1661, 1667 (1993) [here-
inafter Vienna Declaration].
97 International Covenant on Economic, Social and Cultural Rights, Dec. 16,
1966, 993 U.N.T.S. 3, art. 15(1) (entered into force Jan.3, 1976) G.A. Res. 2200A
(XXI), 21 U.N. GAOR Supp. No. 16, U.N. Doc. A/6316 (1966) [hereinafter CESCRI.
98 Vienna Declaration, supra note 96, at 1667; see also CESCR, supra note 97,
art. 15(1).
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and calls for international cooperation to "ensure that human
rights and dignity are fully respected."99 Thus, although the
U.N. as a whole has not yet drafted a specific convention on bi-
omedical research with human subjects, such research is a rec-
ognized problem with broadly articulated basic principles:
human dignity and bodily integrity.
E. Conclusion - The need for a clear set of enforceable
regulations
Although the FDA Rules and the European Convention set
strict standards for studies performed within the United States
and the European Union respectively, these rules do not apply
extraterritorially. 10 0 Furthermore, although the problem of
bioethics is clearly recognized in international treaties, there is
neither a binding international treaty nor an unambiguous set
of customary international rules for multinational drug compa-
nies to follow. Several international guidelines provide the be-
ginning of a framework, but until they are clearly consolidated,
it will remain possible for researchers to pick and choose which
ethical rules to follow. In the absence of binding, enforceable
international rules or guidelines, research abuses will continue
to occur.
III. MEDICAL TESTING IN DEVELOPING NATIONS
There are two primary concerns raised by the internationalization
of human experimentation: first is the potential for the exploita-
tion of subjects in developing countries, and second are differ-
ences in ethical standards between the host and sponsoring
communities. . . it can actually undermine the regulation of
human experimentation by creating an incentive for countries to
underregulate or underenforce scientific research, including re-
search involving human subjects. 10 1
99 Vienna Declaration, supra note 96, at 1667.
100 See, e.g., 21 C.F.R. §312.120 (requiring that foreign studies use the Helsinki
Declaration); see also 15 CFR § 101; and FACING THE 21' CENTURY, supra note 37,
at 224 (noting that only when research is government funded do higher standards
apply outside the United States).
101 Effective International Regulations, supra note 22, at 202.
2001]
15
PACE INT'L L. REV.
A. The Boom of Infectious Diseases and the Need for Family
Planning
"In 1969, the United States Surgeon General announced
that the public health, medical, and scientific communities had
conquered infectious disease. In 1996, the World Health Organ-
ization (WHO) reported that a 'world crisis' in infectious dis-
eases is underway."'01 2 The WHO has observed that diseases
like tuberculosis and AIDS are spreading at an incredible rate
in both the developed and the developing world. 10 3 Tuberculo-
sis was expected to produce ninety million new cases and thirty
million deaths by 2000,104 and AIDS will infect between thirty
and one hundred and ten million people by the year 2000.105 As
these diseases know no borders, drug research to combat these
and other diseases has become increasingly important to devel-
oped nations.10 6
For the governments of developing nations, the research is
often welcome. The percentage of people infected with deadly
diseases in many developing nations is at crisis levels. 07 In
Sub-Saharan Africa, over twenty-two million people were in-
fected with AIDS or HIV at the end of 1999, and an estimated
eleven thousand more people become infected every day.'08 In
South and Southeast Asia, it is estimated that nearly six and
one-half million people are presently infected with AIDS or
HIV.109 Approximately half of these infected people are in In-
dia, where concentrated populations facilitate the spread of the
virus. 110 Even more frustrating for leaders in these developing
nations, the cost of potentially helpful drug treatments is too
high for a substantial portion of their infected population.
Moreover, the government cannot afford the cost of massive
102 David P. Fidler, Mission Impossible? International Law and Infectious Dis-
eases, 10 TEMP. INT'L & COMP. L. J. 493, 494 (1996).
103 David P. Fidler, Return of the Fourth Horseman: Emerging Infectious Dis-
eases and International Law, 81 MINN. L. REV. 771, 775 (1997).
104 Id. at 777.
105 Id. at 780.
106 Id. at 783.
107 See AIDS Initiative, supra note 19.
108 See id.
109 See Pamela Philipose, Irrational Complacency, Irrational Fears, INDLAN Ex-
PRESS, October 22, 1999, available at 1999 WL 5583328.
110 See id.
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medical research to find new treatments.1 11 Enter pharmaceu-
tical companies willing to fund research that can be lifesaving
for the populations of the countries. 112 In 1996, for example,
southern Africa alone received about $2.3 billion from pharma-
ceutical companies researching cures to infectious diseases. 11 3
Another strong concern facing developing nations is a des-
perate need for family planning and affordable contraception. 114
Overpopulation, pregnancy-related deaths, and unwanted in-
fants in poverty-stricken nations are problems that lead govern-
ments to seek outside assistance. 115 Pharmaceutical companies
are often willing to offer such assistance because the women in
such nations are attractive test subjects for new contraceptive
devices. 116
Where difficult circumstances like these exist, governments
may sacrifice human rights to obtain the favor of drug compa-
nies;117 or in the alternative, drug companies may pander to
governments in order to continue their research in less costly
environments."1 In addition, cultural and language barriers
may operate to dehumanize research patients in developing na-
tions. 119 Finally, standards for conducting research in develop-
ing nations may fall far below the requirements in developed
nations. 120
B. The Difficulties of Informed Consent
The principle of informed consent has been ingrained in the
jurisprudence of the developed world since the Nuremberg
111 See Mark Schoofs, Ending the Epidemic, THE VILLAGE VOICE, December 21,
1999, at 57.
112 Kurt Shillinger, African Officials Pursue AIDS Vaccine: Governments are
Skeptical of High-Cost Western Drugs such as AZT and Global Imbalances in Re-
search, PORTLAND OREGONIAN, January 9, 2000, at A16 (noting that one of the larg-
est pharmaceutical companies in the world was considering investing in the area).
113 See Simon Barber, U.S. Pharmaceutical Company Eyes South Africa for
Tests, AFRICAN NEWS. SERV., October 21, 1998, available at 1998 WL 21351167.
114 See Horizon: The Human Laboratory (British Broadcasting Corporation
broadcast, November 5, 1995), available at http://www.africa2000.comINDX/
bbchorizon.html [hereinafter Human Laboratory].
115 See generally id.
116 See id.
117 See Effective International Regulation, supra note 22, at 202.
118 See Shillinger, supra note 112, at 104.
119 See Perley, supra note 33, at 162.
120 Id.
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Code. 121 Nevertheless, problems involving informed consent
are often ignored in developing nations. 122 Some studies have
even questioned the applicability of individual consent in situa-
tions where such a concept is entirely foreign. 123 At least one
study has suggested that in communal societies, like those in
much of Africa and parts of Asia, the consent of the community
is a necessary precursor to individual consent.124 Following
this line of thought, the WHO/CIOMS guidelines do allow con-
sent to be given by a community leader.125
While community involvement may be necessary in certain
societies, requiring only community (or government) consent
raises serious concerns about whether the best interests of the
individual research subjects will be adequately addressed. Con-
sidering the high levels of infectious disease and the costs in-
volved in treating these diseases, community leaders may
sacrifice the best interests of the individual research subjects
for the perceived greater good.126 Furthermore, if consent is
gained from the government rather than from the individual re-
search subjects, such government may not have "the same in-
centive to verify representations of the researchers or to
continually supervise the experiment to ensure that it is being
carried out as planned."' 27 Government officials may even have
an incentive to consent to dangerous research in order to
achieve some official policy.1 28
121 For a discussion of the primacy of consent and the problems with that para-
digm see Richard W. Garnett, Why Informed Consent? Human Experimentation
and the Ethics of Autonomy, 36 CATH. LAW. 455, 455 (1996).
122 See Perley, supra note 33, at 162.
123 See, e.g., Sheila Conway, Principles of Ethics in Research, at http://health.
upenn.edu/bioethics/Museum/Conway/ETHICl-l.HTM (last visited December 31,
2000); see also Ruth Macklin, Is Ethics Universal?, in BEYOND REGULATIONS, supra
note 72, at 27-8 [hereinafter Is Ethics Universal?].
124 See generally Practical Experiences in Obtaining Informed Consent for a
Vaccine Trial in Rural Africa, 336(5) NEW ENG. J. MED. 43 (January 30, 1997).
125 See Changing Landscape, supra note 38, at 125.
126 See, e.g., African AIDS Sufferers Perplexed with Government's AZT Stance,
NEWSDAY, December 12, 1999, at A25. See also Changing Landscape, supra note
38, at 125 (1992); see also Barton Gellman, S. African President Escalates AIDS
Feud; Mbeki Challenges Western Remedies, WASH. POST, April 19, 2000, at Al,
available at 2000 WL 19604435. These articles discuss the position of the South
African government, which has criticized proven AIDS treatments.
127 See Effective International Regulation, supra note 22, at 192.
128 See Rachel Baggaley & Eric von Praag, Antiretroviral interventions to re-
duce mother-to-child transmission of human immunodeficiency virus: challenges
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The offering of birth control through government family
planning programs has proven particularly problematic because
of the government's desire to decrease birth rates. The contra-
ceptive device Norplant was tested in the slums of both Ban-
gladesh and Haiti, prior to its release in the developed world. 129
In Bangladesh, one native doctor began to hear disturbing sto-
ries about women who had been given the Norplant insert, but
had been denied removal of the insert on their request. 130 Her
investigation resulted in a military raid of her offices and in
several threats from the government. 131 Research trials in Ha-
iti involved similar scenarios of women suffering adverse side
effects from Norplant, yet being denied removal of the insert. 132
These studies highlight the dangers posed by governmental
desires that override the wishes of research subjects.
Even when researchers do go directly to potential research
subjects for consent, language barriers and cultural differences
may impede true understanding of the testing procedure. 33
Such lack of understanding is evident in the stories of many
subjects of a placebo-controlled tuberculosis study in Ugan-
da. 1s4 One English-speaking, university-educated test subject
stated that he had understood the word "placebo" to be a "medi-
cal word that I was not required to know."1 35 Others thought
that "placebo" was simply a different drug that they were being
given. 136 Few of the subjects, if any, understood that they could
be part of the control group that would receive Vitamin C tab-
lets instead of the proven medical treatment. 137
Researchers may not be able to explain to test subjects that
they might be placed in a control group not receiving treatment.
for health systems, communities and society, BULLETIN OF THE WORLD HEALTH
ORG., August 1, 2000, at 1036 (discussing the problem in the context of mother-to-
infant HIV transmissions, the authors note "some countries may claim a compel-
ling interest in protecting the health of unborn children, and in this circumstance
it is conceivable that HIV-positive women would be forced to accept anti-retroviral
drugs.").
129 See Human Laboratory, supra note 114.
130 See id.
131 See id.
132 See id.
133 See Perley, supra note 33, at 162.
134 See Ugandan Study, supra note 17, at 1A.
135 Id.
136 See id.
137 See id.
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One researcher involved in the tuberculosis tests recalled tell-
ing patients they could receive a drug that was "nothing."138
The patient subjects interviewed, however, understood only
that they were receiving treatment. 139 Finally, the promise of
medical care and the free examinations that often accompany
drug testing may serve as inducements that render true, volun-
tary consent unlikely.1 40
While informed consent may appear to be only a signature
on a piece of paper, a mere formality that pales in comparison to
the threat of AIDS and like diseases, the reality is much differ-
ent. Dire consequences have resulted from the testing of drugs
where doctors have not been required to obtain fully informed
consent. 41 In many circumstances, informed consent serves as
a check on unethical testing. 42 If drug companies cannot ob-
tain willing subjects for their research projects after full disclo-
sure, such projects should not be conducted at all. 143
C. Use of Placebos and The Issue of Standard of Care
Much of the recent controversy surrounding drug testing in
developing countries involves the standard of care and the use
of placebo control groups. At issue is the ethical guideline re-
quiring that control groups be given the best possible treat-
ment. 44 Recent debate has centered around fifteen placebo-
controlled tests145 that involved administering a shortened, less
costly course of an antiviral drug to pregnant women in an at-
tempt to stop the transmission of AIDS to their unborn chil-
138 Ugandan Study, supra note 17, at 1A.
139 Id.
140 See Effective International Regulation, supra note 22, at 201-02; see also
Dickens, supra note 21, at 193.
141 See Michelle D. Miller, RN, MPH, The Informed Consent Policy of the Inter-
national Conference on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use: Knowledge is the best Medicine, 30 CORNELL
INT'L L. J. 203, 219 (1997).
142 See id.
143 See id.; see also Dickens supra note 21, at 195.
144 See Helsinki Declaration, supra note 38, sec. II, para. 3. For the debate as
it has appeared in the medical community, see generally Clinical Research, supra
note 9, 578-583 (use of placebos deemed unethical), but see Harold Varmus &
David Satcher, Ethical Complexities of Conducting Research in Developing Coun-
tries, reprinted in TuSKEGEE's TRUTHS, supra note 9, 584-588 (use of placebos
deemed ethical).
145 See Fairchild & Bayer, supra note 13, at 598.
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dren.146 Included in the tests were placebo groups, the
members of which would receive no medication at all.
147
A few years prior to these experiments, tests completed in
the United States demonstrated the effectiveness of giving
mothers a full course of zidovudine (AZT)2 48 Those tests
showed that the full course of the drug almost completely elimi-
nated the transmission of HIV to the child. 149 Subsequent to
these findings, the use of the longer AZT treatment became
standard in developed countries. 15 0 Thus, the tests using pla-
cebo groups instead of control groups being given the longer
treatment regime would have been considered unethical in the
developed world because the best possible treatment was not
being given to the control group.
Those criticizing the placebo-control research note that re-
searchers funded by money from the United States have an eth-
ical duty to provide the same standard of care to research
subjects in developing nations as would be given in the United
States. 15 ' These critics also point out that the women in the
placebo groups will receive no treatment, despite the fact that
effective treatment does exist. As a result, these women and
their babies are likely to die.' 52
Defenders of the placebo-control tests offer a two-fold argu-
ment for denying AZT treatment to the control groups during
the research trials. First, it is argued that such treatment is too
costly to be standard treatment in the test countries. 153 The
cost of a standard, long course treatment of AZT for one preg-
146 See David Brown, Short-Term Drug Therapy Cuts Infants' Risk of AIDS,
CHICAGO SuN-TIMES, February 3, 1999 at 52. The shortened course was AZT dur-
ing the last few weeks of pregnancy.
147 See id. The United States, Denmark, France, South Africa, and the United
Nations Program on Acquired Immune Deficiency Syndrome funded these tests.
See Fairchild & Bayer, supra note 13, at 598.
148 See Brown, supra note 146, at 52. A full course was AZT during the last
trimester of pregnancy.
149 Id.
150 See Clinical Research, supra note 9, at 579.
151 See David M. Studdert & Troyen A. Brennan, Clinical Trials in Developing
Countries: Scientific and Ethical Issues, 169 MED. J. AUSTL. 545-548 (Nov. 16,
1998), available at http://www.mja.com.au/public/issues/novl6/studdert/studdert.
html.
152 See id.
153 See Varmus & Satcher, supra note 144, at 587.
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nant woman is between $400 and $900.154 In Sub-Sahara Af-
rica, however, the funding available for medical treatment
amounts to approximately $14 per person per year. 155 In deny-
ing the treatment to the control groups, therefore, it is argued
that the pregnant women in these control groups are in no
worse position than they would ordinarily be. 156 Second, as one
researcher noted, if all test subjects were to receive AZT treat-
ment, it would be nearly impossible for researchers to deter-
mine whether the new treatments being tested were better than
no treatment at all. 15 7
Placebo-controlled tests conducted in Uganda to determine
the effectiveness of new tuberculosis drugs present an even
greater stretch of ethical boundaries. Despite the fact that ef-
fective tuberculosis treatments were available prior to the test-
ing, control groups of Ugandan tuberculosis patients with AIDS
received no treatment at all. 158 In contrast, virtually identical
tests had previously been conducted in fifty-two locations
within the United States, Mexico, Haiti and Brazil, 15 9 and in
none of these tests had the researchers deemed it necessary to
give placebos to any of the patients. 160 The control groups in
these tests received the standard twelve-month treatment. 16'
Without leaving any patients vulnerable to untreated tubercu-
losis, the United States, Mexico, and Haiti tests successfully
concluded that a two-month supply of the new tuberculosis
drugs was as effective as a twelve month supply of the old
drugs. 162
In Uganda, on the other hand, patients were left untreated
for at least nineteen months while U.S. researchers tracked the
154 See Dennis R. Cooley, Second Best: A Case for Lowering Testing Standards
in Third World Countries, Paper presented at the 2 0th World Congress of Philoso-
phy (Aug. 15, 1998), available at http://www.bu.edu/wcp/Papers/Bioe/BioeCool.
htm.
155 See id.
156 See Varmus & Satcher, supra note 144, at 586.
157 See Kim Dalton, AZT Trials in the Third World: Tuskegee Redux or Cheap
Shot?, available at http://www.columbia.edu/cu/21stC/issue-3.3/dalton.htm.
158 See Ugandan Study, supra note 17, at 1A.
159 See id.
160 See id.
161 See id.
162 See id.
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course of the disease. 163 Researchers in Uganda defended the
decision on the grounds that the Ugandan government required
a placebo group before testing would be allowed. 164 This dichot-
omy between the treatment of test subjects in the developing
world and the treatment of those in the developed world has led
at least one researcher from the Center for Disease Control to
comment, "Is it possible that a study that is 'unethical' in one
socioeconomic and epidemiologic setting can be 'ethical' in a dif-
ferent setting?"1 65
This cultural relativism has been widely defended and criti-
cized.1 66 As noted by a prominent civil rights attorney, Fred D.
Gray, formerly involved in lawsuits pertaining to the Tuskegee
experiments, "A human life in a foreign country is as valuable
to them as our lives are in this country."1 67 Rather than insist-
ing on the best possible treatment for the individual test sub-
jects as patients and people, the individual becomes an
unacceptable means to an end-the development of a drug or
the pleasing of a government official.' 68 Meanwhile, those re-
ceiving placebos unnecessarily are left at risk to fully develop a
disease, or worse yet, to die from an existing disease for which
there is effective treatment.
169
D. The Use of Vulnerable Populations
One ethical problem with clinical tests in developing na-
tions is that the people of these nations, by their circumstances,
constitute vulnerable populations. They are, therefore, entitled
to a higher standard of care.170 Following the public disclosure
163 See Ugandan Study, supra note 17, at 1A.
164 See Tuberculosis Study, THE PORTLAND OREGONIAN, November 26, 2998, at
A09, available at 1998 WL 20388040. In fact, the cost of the tuberculosis treat-
ment was relatively inexpensive. See id.
165 Ugandan Study, supra note 17, at 1A (quoting a researcher from the Center
for Disease Control).
166 See Clinical Research, supra note 9, at 580-81.
167 See Ugandan Study, supra note 17, at 1A.
168 See Marcia Angell, Editorial Responsibility: Protecting Human Rights by
Restricting Publication of Unethical Research, in NAzI DOCTORS, supra note 5, at
277.
169 See Ugandan Study, supra note 17, at 1A.
170 See Fairchild & Bayer, supra note 13, at 597 ("In the case of Third World
trials to prevent maternal-fetal HIV transmission, two core elements of Tuskegee
were at issue: the exploitation of impoverished vulnerable populations and the de-
nial of access to effective treatment.").
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of the Tuskegee experiments, the Belmont Report was is-
sued. 17 1 This report contained three principles for research-
autonomy, beneficence, and justice. 172 Inherent in the concept
of justice is the protection of vulnerable populations from bear-
ing a disproportionate share of medical research.' 73 Not only
are the people of developing nations subject to an extraordinary
amount of medical research, but much of that research centers
on women and children.
Under the Bioethics Guidelines, women (particularly preg-
nant women) and children are accorded special protections dur-
ing biomedical testing.174 The Epidemiological Guidelines also
note the importance of protecting vulnerable populations. 175
Protection of vulnerable populations is not, however, a new con-
cept. The United Nations Convention on Economic, Social and
Cultural Rights (CESCR), states:
"Special protection should be accorded to mothers during a rea-
sonable period before and after childbirth... Special measures of
protection and assistance should be taken on behalf of all children
and young persons... Children and young persons should be pro-
tected from economic and social exploitation." 176
Achieving protection may, however, be difficult in those nations
in which women are viewed as the property of their hus-
bands. 77 In these circumstances, partners may pressure wo-
men not to get tested for AIDS or enter clinical trials so as to
avoid the social stigma of such diseases.178 Alternatively, male
partners may push women to take part in the studies, regard-
less of the woman's desire. 179 This concern is particularly rele-
vant when a woman is pregnant, as the father of the unborn
child may force the woman to undergo treatment for the benefit
of the child, ignoring the potential consequences for the wo-
171 See generally JONES, supra note 10.
172 See id.; see also Conway, supra note 123.
173 See Conway, supra note 123.
174 See International Ethical Guidelines, supra note 72, at guidelines 5, 11.
175 See Epidemiological Guidelines, supra note 79, at preamble.
176 See CESCR, supra note 98, art. 10.
177 See Ruth Macklin, Universality of the Nuremberg Code, in NAZI DOCTORS,
supra note 5, at 251[hereinafter Universality of Nuremberg].
178 See Baggaley & Von Praag, supra note 128, at 1036.
179 See id.
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man.180 Under such circumstances, principles of confidentiality
and consent are difficult to uphold.18 1
An inability to obtain valid consent from women is particu-
larly problematic in the context of family planning because the
failure to obtain consent amounts to a failure to protect bodily
integrity. In the Norplant test in Bangladesh, for example, the
data of the sponsoring organization indicated that the repeated
requests of over one hundred women for removal of the Nor-
plant device were refused. 82 One researcher fighting the Nor-
plant trials in Bangladesh told British Broadcasting
Corporation reporters, "our woman [sic] are cheaper here
... they can be easily controlled and their bodies can be easily
tested."183
Birth control is not the only area of concern when women
are involved in research. With medical resources scarce in
many developing nations, those seeking basic medical treat-
ment may regard clinical trials as the only avenues by which
they may obtain such treatment. In order to protect their un-
born children, pregnant women, particularly those infected with
AIDS, are often the most willing to participate in any medical
test offering a ray of hope.184 Thus, a disproportionate number
of the participants in research trials in African or Asian coun-
tries are pregnant women and their unborn children.
185
While participation in clinical trials can be life saving, dan-
gers do exist. Many women have no other realistic means of
receiving normal health care for themselves or their children,1
8 6
thus, they may feel that they are being coerced into participat-
ing in drug research simply to receive basic medical care.187 In-
formed consent, therefore, is potentially lacking. Furthermore,
while the effects upon adult women are often considered in the
development of drugs and vaccines, the effects of the same
180 See id.
181 See Universality of Nuremberg, supra note 172, at 251.
182 See Human Laboratory, supra note 114.
183 See id. (quoting Farida Akhter).
184 See Dickens, supra note 21, at 193; see also Brown, supra note 146, at 52;
and FACING THE 21' CENTURY, supra note 37, at 115-17.
185 See Effective International Regulation, supra note 22, at 194.
186 See Wendy K. Mariner, AIDS Research and the Nuremberg Code, in NAZI
DOCTORS, supra note 5, at 295.
187 See id; see also Baggaley & von Praag, supra note 128, at 1036.
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drugs and vaccines on pregnant women and their fetuses are
often unknown.188 The dangers of testing drugs with unknown
side effects on pregnant women and their unborn children are
well-documented. 189
Children may also be particularly vulnerable. In the first
place, it is questionable whether or not children are even capa-
ble of consenting to research performed on them.' 90 The special
situation of children and research has frequently been ad-
dressed. The European Convention, for example, recognizes the
particular vulnerability of children. It requires that children
only be used when the research provides a direct benefit to
them and only when no other comparable research can be con-
ducted on adults. 191 The Convention on the Rights of the Child
also requires that children be afforded special protection.' 9 2
The FDA Rules require that the Independent Review Board
(IRB) ensure that the consent of a parent or legal guardian is
obtained, 193 that there be an additional showing that there is no
other way to conduct the research, 194 and that the research is
for the benefit of the child.195 Finally, the Bioethics Guidelines
include similar provisions requiring both consent and a demon-
stration that alternative methods of research are lacking.196
In addition to the concerns expressed in the various inter-
national Conventions and Guidelines, the use of children in re-
search raises practical scientific concerns. Most drugs are
tested in the laboratory solely for their effect on adults. 197 The
effects on children, like those on the fetus, are usually not the
top priority of researchers. Rather than specifically considering
the potential effects of the experimental drugs on children as
188 See, e.g., FACING THE 21' CENTURY, supra note 37, at 118, detailing the
development and release of Thalidomide.
189 See id. Thalidomide was a drug given to pregnant women to control morn-
ing sickness. It caused severe birth defects in over 8,000 babies. See id.
190 See Effective International Regulation, supra note 22, at 192.
191 See European Convention on Biomedicine, supra note 61, at art. 17.
192 See generally Convention on the Rights of the Child, G.A. Res. 44/25, annex,
44 U.N. GAOR, Supp. No. 49) at 167, U.N. Doc. A/4449 (1989), reprinted in 28
I.L.M. 1448 (1989).
193 See 21 C.F.R. §46.408.
194 See 21 C.F.R. §46.407.
195 See 21 C.F.R. §46.406.
196 See International Ethical Guidelines, supra note 72, at guideline 5.
197 See FACING THE 2 1 1 CENTURY, supra note 37, at 116.
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opposed to adults, researchers may simply use smaller dosages
when using children for research. For many drugs, however,
simply giving a child a smaller dose will not appropriately ad-
dress health concerns. 198
E. Determining the Beneficiaries of the Treatment
For a clinical trial to be justly administered, it must be con-
ducted only on a population likely to benefit from the specific
research being conducted. 199 Thus, tests in the developing
world must be capable of solving problems in the community
where the test occurs, and the solution must be one that will be
realistically available to the community. 200 Diseases such as
AIDS present difficulties in this respect because there are sev-
eral strains of the disease.201 A drug may be effective on one
strain, but not on others. 20 2 This problem begins to affect devel-
oping nations when their citizens are used to find cures for the
strains of diseases not present in their own nations, but rather
for strains present in the developed world.20 3
Strains of AIDS common in developed nations often differ
from those present in developing African nations.20 4 Yet, the
vaccines tested in these developing nations are generally in-
tended to produce treatments for the strains of disease present
in developed nations.20 5 Thus, the very people on whom the
drugs are being tested will not, in many cases, receive any bene-
fit from the drug. Nor will the developing nations that allow
large pharmaceutical concerns to perform research within their
borders derive any benefit for their citizens from the research.
This situation represents a direct violation of those provisions of
the Bioethics Guidelines and the Epidemiological Guidelines re-
quiring that the benefit to the subject population be propor-
tional to the risk that population bears.20 6
198 See id.
199 See Conway, supra note 123.
200 See id.
201 See Dickens, supra note 21, at 192.
202 See id.
203 See id.
204 See id.
205 See id.; see also Henderson, supra note 20.
206 See International Ethical Guidelines, supra note 72, at guideline 10; see
also Epidemiological Guidelines, supra note 79, at preamble.
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Why would a government allow research to occur for
strains different from those within its borders? First, many de-
veloping nations are absolutely dependent on the help of the
pharmaceutical concerns of developed nations for any drug
treatments. 20 7 Such nations cooperate with the research of
pharmaceutical concerns to ensure that their citizens receive at
least a modicum of medical protection. Secondly, government
officials in developing nations may hope that a cure for one
strain will lead to a cure for others, or that a side effect of serv-
ing as a testing ground for developed nations will be the discov-
ery of a solution for their own problems. Finally, the
governments of developing nations are probably aware that the
subjects of the trials likely fail to understand that they are be-
ing treated for strains of the disease different from the strain
with which they are afflicted. 208 Such popular ignorance may
reduce fears of political backlash.
Furthermore, pharmaceutical researchers could take ad-
vantage of popular ignorance and government acquiescence to
test potentially dangerous levels of new drugs. For example,
some have leveled accusations at pharmaceutical concerns
claiming that women in developing nations are being used to
test the doses of hormone levels in advance of similar testing in
the developed world.209 If such accusations are accurate, it
would be quite clear that a lesser value is being placed on the
health and the lives of the research subjects in the developing
nations.
Another very real problem is whether a particular drug is
realistically available for use by the host country. Again, the
issue of resources is at the heart of the problem. In the case of
the tuberculosis studies, there was no evidence that the
Ugandan government intended to use the drug being tested, or
even that it had any ability at all to do SO. 2 1 0 While not all re-
searchers agree, many researchers believe that the testing of
drugs in developing countries which are realistically only of use
207 See AIDS Initiative, supra note 19.
208 See Perley, supra note 33, at 162.
209 See Human Laboratory, supra note 114.
210 See Ugandan Study, supra note 17, at 1A.
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only to developed nations is a violation of "our most basic under-
standing of ethical behavior."211
F. Governmental Pressures in Developing Nations
Even when researchers attempt to act according to the
highest ethical standards, they may encounter problems within
the host country. The importance of maintaining good relation-
ships with the host country government often takes precedence
over the rights of the individual research subjects. 212 A leading
researcher at Johns Hopkins University described the problem
succinctly, "You often end up having to do studies that may not
be absolutely scientifically necessary but are needed to convince
people it's the right thing to do."21 3 In other words, drug tests
are often conducted simply because the government officials
want them done.
A situation involving the government of South Africa and
the testing of an anti-AIDS drug is instructive. 214 The Health
Minister of South Africa has refused to allow doctors to provide
a drug known to prevent the contraction of AIDS to rape survi-
vors unless there is a control group of rape victims who do not
receive the drug.215 Doctors protest the use of a control group
calling it "tantamount to murder."21 6 The doctors specifically
note the existence of data that shows the drugs will prevent the
contraction of AIDS, and they lament the denial of medication
to women who have "fought so hard to live and to survive the
rape."21 7 Nevertheless, while doctors and government officials
debate, the $100-million dollar grant from pharmaceutical com-
panies remains unused, and more and more women are each
day denied a chance to receive the life-saving drug.218 Quite
simply, doctors and medical researchers are often caught be-
tween firm adherence to ethical testing procedures and at-
211 See Varmus & Satcher, supra note 144, at 584.
212 See Ugandan Study, supra note 17, at 1A (quoting Dr. Neal Halsey).
213 See id.
214 See Charlene Smith, Zuma Resist Rape /HIV Studies, AFRICAN NEWS SERV.,
May 21, 1999, available at 1999 WL 17314778.
215 Id.
216 Id.
217 Id.
218 Id.
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tempting to placate those government officials without whose
cooperation no testing at all would occur.2 19
IV. RESPONDING ETHICALLY
A. The Recognition of the Importance of Ethics
When dealing with any transnational endeavor, questions
about applicable rules always arise. 220 Nowhere is this more
true than in medical ethics. 221 Nevertheless, despite the exis-
tence of real cultural differences, it has been argued "that the
ethical requirements for human subjects research rest on uni-
versal ethical principles. ' 222 Such universal principles would
include the principles of human dignity and bodily integrity.
The recognition of universal ethical principles is an important
first step in their application to transnational research.223
Without this recognition, any regulation undertaken by one
country, even when limited in effect to its own researchers, is
subject to the charge of cultural imperialism. 224 On the other
hand, if international agreement regarding the primacy of the
human being is reached, meaningful rules for the field of trans-
national bioethics can be formulated and enforced. 225
B. An International Legal Regime
Perhaps the greatest problem facing international bioethics
regulation is the fact that no enforceable international law ex-
ists, and no enforcement mechanism is in place. 226 This has
prompted some to call for the creation of an internationally
binding document. M. Cherif Bassiouni, for example, has
drafted a convention for the prevention of unlawful human
219 Id.
220 See generally Is Ethics Universal, supra note 123, at 23-7 (discussing some
of the conflicts in ethical principles when research is conducted internationally).
221 See generally id. at 23-4.
222 Id. at 24.
223 For a detailed analysis of the difference between the universality of bioethi-
cal principles and the non-universality of bioethical procedures, see id.
224 See id. at 27.
225 For an assessment of the problem with allowing countries to claim cultural
relativism, see generally id.; see also Universality of Nuremberg, supra note 177, at
253.
226 See Effective International Regulation, supra note 22, at 185.
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rights experiments. 227 Others have called for the addition of a
protocol to Article 7 of the ICCPR. 228 Finally, still others have
noted the need for either a statute to the new International
Criminal Court or a permanent international tribunal to hear
international violations of medical research ethics. 229
Whatever the form such a binding agreement and enforcement
mechanism should take, it is becoming increasingly evident
that countries cannot deal with these problems on their own.230
C. Regulation of Nationals
The WHO/CIOMS states that pharmaceutical testing con-
ducted in developing nations by researchers from developed na-
tions must meet the standards of both the home nation as well
as those of the developing nation hosting the research. 231 To
actually follow these guidelines, researchers within the United
States would be bound by the FDA Rules and those in Europe
would be required to follow both the European Convention and
their own national research laws. All researchers would be re-
quired to abide by the laws of the individual developing nations
in which the research is performed. Unfortunately, however,
unless a nation formally adopts the WHO principles as law,
they are not binding, but merely suggestive. 232 Widespread
adoption of such principles by the governments of developing
nations is, therefore, necessary in order to create a uniform
standard for research in developing nations.
Developed nations, however, need not rely on developing
nations to adopt ethical principles in order to regulate their own
doctors, researchers, and corporations. It has long been a tenet
of international law that a state may exercise jurisdiction over
its citizens and its corporate entities wherever they may be lo-
cated. 233 "The nationality of a corporation (more so than the
nationality of its employees) is (or should be) an important con-
sideration in determining the degree to which domestic laws
227 See Perley, supra note 33, at 166.
228 See Effective International Regulation, supra note 22, at 11.
229 See Annas & Grodin, supra note 30, at 118.
230 See id.
231 See International Ethical Guidelines, supra note 72, at guideline 15.
232 See id.
233 See P. T. MICHULINSKI, MULTINATIONAL ENTERPRISES AND THE LAw 124
(1996).
20011
31
PACE INT'L L. REV.
and standards apply extra-territorially." 234 Thus, the govern-
ments of the United States and of European nations could
choose to force drug companies to comply with national laws re-
garding consent, the use of placebos, and the implementation of
testing safeguards for vulnerable test populations. 235
As is true of most international law, the principle of extra-
territorial regulation of nationals is not absolute.236 It has been
toned down by the "rule of reasonableness." 237 This rule re-
quires nations using extraterritorial laws in the regulation of
their nationals to yield their laws when enforcement would "un-
reasonably interfere with the interests of other states."238 The
rule requires a balancing approach to consider which nation's
interests should prevail. 239 Under this rule, however, at-
tempted enforcement of bioethics principles in order to protect
the individual human rights of subjects is likely to be deemed
"reasonable." The governments of developed nations should,
therefore, insist that their pharmaceutical concerns and their
researchers conduct research under the highest possible stan-
dard of ethics. 240
D. Solutions from the Research Community
While legally enforceable regulations could solve medical
research problems involving individual companies, in the larger
picture something more is needed. The world of biomedicine is
inherently an ethical one.241 Thus, "authorities that seek to
persuade, cajole, and shame can do more to create effective pol-
icy than those that exercise coercive power."242
234 Mark Gibney & R. David Emerick, The Extraterritorial Application of
United States Law and the Protection of Human Rights: Holding Multinational
Corporations to Domestic and International Standards, 10 TEMP. INT'L & COMP.
L.J. 123 (1996).
235 See MICHULINSKI, supra note 233, at 124.
236 For a fairly complete treatment of the use of laws that operate extraterrito-
rially to regulate nationals, see A.V. LOWE, EXTRATERRITORIAL JURISDICTION (1983).
237 See THE EXTRATERRITORIAL APPLICATION OF NATIONAL LAWS 46-7 (Dieter
Lange & Gary Born, eds. 1987).
238 Id.
239 Id.
240 See Gibney & Emerick, supra note 234, at 124.
241 See Robert Schwartz, Bioethics Policy: Looking Beyond the Power of Sover-
eign Governments, 33 Hous. L. REV. 1283, 1284 (1997).
242 Id.
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The refusal of reputable medical journals to publish test re-
sults from unethical experiments would go far to prevent the
research from taking place. 243 The Second Helsinki Declaration
recognized this concept with its admonitions that "[rieports not
in accordance with the principles laid down in this Declaration
should not be accepted for publication."244 As most researchers
compete for limited funding, and as most funding is contingent
on past success (as evidenced by publication), such a refusal can
have great practical effect. 245 Many reputable journals already
adhere to the Helsinki principles, 246 and continued adherence is
important as it demonstrates that research is not justified by its
conclusions. 247 This principle cannot be ignored when research
is conducted in developing nations.248
E. Necessary Rules
When attempting to create enforceable ethical rules for
drug trials in developing nations, some principles should take
priority. First, informed consent does not in and of itself justify
unethical research. While informed consent is certainly a ne-
cessity, no one should be asked to consent to a study that is of
no meaningful benefit either to the subjects of the study or to
the greater community involved. If people were not asked to
participate in such studies, concerns about people consenting
solely for the purpose of receiving medical treatment would
likely be diminished.
In order to ensure that research is conducted in an ethical
manner, the U.S. National Bioethics Advisory Commission has
issued recommendations for guidelines that would require re-
searchers to submit an explanation of how the treatment, if suc-
cessful, will be made available to the host country. 249 This
recommendation has sparked a serious out-cry, but it actually
243 For a comprehensive analysis of this issue, see Angell, supra note 168, at
276.
244 See Helsinki Declaration, supra note 38, at principle 8.
245 See Angell, supra note 168, at 279.
246 See Clinical Research, supra note 9, at 581.
247 See id.
248 See id.
249 See, e.g., Gretchen Vogel, Stricter Rules for Third-World Trials?, SCIENCE
DAILY INSIGHT, (Oct. 2, 2000), at http://www.apnet.com/inscight/10022000/graphb.
htm (quoting several researchers).
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represents the highest ethics. If a drug is incapable of use by a
host country, using the people of that country to test the drug
renders them little more than guinea pigs. While at least one
bioethicist has commented, "If people are consenting . . . the
whole assumption that somehow we owe them something seems
illogical,"250 such an opinion shows a callous disregard for those
participating in clinical trials. Researchers clearly owe a duty
to those persons involved in a study to conduct research accord-
ing to the highest ethical standards, and to perform such re-
search for the benefit of their subjects' communities.
Second, where there is reason to believe that a community
or government is compromised in giving informed consent, such
as where there is a health crisis or a government policy at issue,
informed consent should be obtained directly from those who
would participate in the trial. Some members of the commu-
nity, particularly women, may not feel entirely comfortable giv-
ing consent on their own, but researchers can address this
problem by spending time in dialogue with the host community.
Such dialogue could be modeled after researchers' experiences
with poor communities within the United States. 251 The use of
community review boards and attempts to create a dialogue
with the specific research population prior to the beginning of
the research can improve cooperation during the research. 252
Such an approach allows people and local government leaders
to feel invested in the research, rather than simply subjects of
it.253 The open dialogue approach could also help to allay some
of the problems with host governments. Where a government is
educated as to the nature and purpose of the research, and
where host country doctors are included in the trial, the result
is likely to be greater understanding and adherence to ethical
procedures. This approach is already being used in some com-
munities. 254 In some South African villages, for example, field
250 See id. (quoting bioethicist Norman Frost of the University of Wisconsin,
Madison).
251 See generally Community-based HIV Research, in BEYOND REGULATIONS,
supra note 72, at 83-107.
252 See id. at 95. For the complete story of how community based research was
conducted in underdeveloped communities within the United States, see id. Also,
note the problems created when a review board begins to be a part of the research
team rather than representatives of the community. See id. at 104-05.
253 See id. at 101.
254 See Smith, supra note 214, at A16.
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workers have spent more than a year preparing the community
for a possible AIDS vaccine program that is not even developed
yet.255
In addition to proper preparation, it is important that the
host community not believe that it will be abandoned after the
researchers leave. Willingness to train indigenous medical per-
sonnel to ensure care after the researchers have departed can
also contribute to better cooperation. 256 Additionally, such
training will provide a community with lasting benefits from a
research project even if the vaccine being tested proves
ineffective. 25 7
V. CONCLUSION
The ethical problems of research in developing countries
are far from being solved. As this article is completed, a Penn-
sylvania drug company has asked the FDA to approve clinical
trials in Latin America of a new treatment for infants with life-
threatening lung illnesses.258 The company has requested that
a placebo group be approved, despite the existence of known
treatments for the disease. 259 Perhaps most disturbing, the
company can perform the tests even without FDA approval.
260
Similar trials in Europe will not involve placebos. 261 The FDA
is still considering the experiments. 262
Perhaps the most important solution to the ethical dilem-
mas in medical research is awareness. Pharmaceutical compa-
nies are as subject to political and public pressure as the next
profit-seeking enterprise. Furthermore, researchers are often
dependent on university or government funding. As political
and public pressure can influence funding decisions, the exer-
tion of such pressures on universities and governments will ef-
fectively control the nature and manner of the research being
performed. An insistence by people in developed nations that
the rights of people in other countries be respected is, in actual-
255 See id.
256 See Dickens, supra note 21, at 194.
257 See id.
258 See Flaherty & Stephens, supra note 24, at A03.
259 See id.
260 See id.
261 See id.
262 See id.
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ity, simply an insistence that there be no deviation from stan-
dards that protect all people from dangerous research. It is only
too easy to justify unethical research at home once it has been
performed abroad. Vigilant adherence to basic protections in
medical experiments ensures that no one will become a victim
of unethical research.
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